What changed
At the World Lung Cancer Congress in Seoul on September 13, Professor Zhang Li of Sun Yat-sen University Cancer Center presented results from the phase III TAISHAN-302 trial of YL201 (依康坦博妥塔单抗, or Tam-Peli) in recurrent small-cell lung cancer. The trial is the first worldwide to report phase III clinical data for a B7-H3-targeting antibody-drug conjugate (ADC), according to China News Service.
Compared with topotecan, YL201:
- Reduced the reported risk of death by 54%.
- Reduced the risk of disease progression by 71%.
- Produced a 59.1% objective response rate.
- Lowered grade 3-or-higher treatment-related adverse events to 46.4%, versus 74.7% for topotecan.
Anne Chiang, an associate professor at Yale School of Medicine, said in the conference’s official summary that a new treatment option for recurrent small-cell lung cancer had emerged. The report does not establish whether regulators or treatment guidelines have adopted YL201 as a standard.
A second Chinese B7-H3 ADC, Hansoh Pharma’s HS-20093, was also selected for the WCLC chair’s forum. The two studies used the same disease setting and comparator, presenting a broader showing by Chinese developers in the field.
The commercial terms show what each party contributed and received: Duality Biologics, known in Chinese as Yilian Biologics, granted Roche an exclusive global license to its YL201 program; Roche provided upfront consideration and recent milestone payments totaling $570 million, while Roche received global development and commercialization rights under the agreement. The report says the deal set a record for the upfront payment for a domestically developed single-target ADC and that Yilian’s total out-licensing collaborations have exceeded $10 billion.
Why it matters
B7-H3 is widely expressed in tumors including small-cell lung cancer, esophageal squamous-cell carcinoma and nasopharyngeal cancer, while having limited distribution in normal tissue. That makes it an attractive drug target, but development has been difficult: blocking antibodies have shown limited efficacy, ADC programs face risks including lung toxicity, and the target’s biological role remains incompletely understood.
The result therefore provides an important test of whether Chinese drugmakers can convert difficult targets into late-stage clinical benefit. Of more than 20 B7-H3 ADC programs in global clinical development, nearly 80% are led or co-developed by Chinese companies, according to the report. The broader shift is from licensing early technology abroad toward global co-development and worldwide product planning.
The result also strengthens the commercial case for Chinese companies retaining meaningful ownership of high-risk innovation. If the findings withstand regulatory review and broader clinical use, YL201 could improve the negotiating position of Chinese developers in global partnerships. It could also encourage further investment in less-established targets rather than concentrating only on validated pathways such as HER2.
What to watch next
The key tests are regulatory review, additional confirmation of the survival and safety results, manufacturing, and whether physicians adopt YL201 in routine treatment. The outcome will also show whether B7-H3 becomes a durable ADC class opportunity or whether YL201 remains a single-product success.
The WCLC presentation places YL201 ahead of other B7-H3 ADC programs in publicly reported phase III evidence. HS-20093 and other competing programs will indicate whether Chinese developers have established a broader lead in the target, while the terms and results of future global partnerships will show whether that scientific lead translates into sustained commercial influence.
Comments
No comments yet.